
#News for #investors and #media: Today, we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer. Learn more: gsk.to/4CacNpT

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: gsk.to/socialmedia

#News for #investors and #media: Today, we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer. Learn more: gsk.to/4CacNpT

#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD). Find out more in the press release: gsk.to/4egVmcZ #TLM26

News for #Investors and #Media Watch our CEO, Luke Miels, as he delivers news of our strong Q3 performance and continued momentum ⤵️ Find out more: gsk.to/4zggYib #GSKResults #Earnings

#News for #Investors and #Media: Today @US_FDA has approved our first-in-class treatment for chronic hepatitis B (CHB). This approval reflects our commitment to innovation in liver disease, where significant unmet need remains. Learn more: gsk.to/4z5NgfC

#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4zCl4Rf

Building on our $30 billion commitment to US innovation, R&D and manufacturing, today we are celebrating the development of our Upper Merion Flex Factory. By expanding our presence in Pennsylvania, this factory will deliver best-in-class new medicines for respiratory disease and cancer. @GovernorShapiro @PAChamber @TradeGov @montco_pa @ChamberPHL @SelectUSA

#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/4gO7q71

On World Hepatitis Day, we’re raising awareness of viral hepatitis and recognizing the importance of early and more complete testing in hepatitis B. Learn more about complete testing at: hepatitisbtesting.com #WorldHepatitisDay #HepB #HepatitisB #LiverHealth #TestingMatters

Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge. Find out more: gsk.to/4pG56BQ #Q2Results $GSK

#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. Find out more in the press release: gsk.to/4fdROcs Our mission: to leave no person living with HIV behind.

#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: us.gsk.com/en-us/media/press…

#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/4eoSdHf

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/4dQBSLg.

Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management. At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.